- RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
This study looks at a new treatment called BMS-986353 for severe Systemic Sclerosis. It compares this new treatment with standard care to see if it's more effective and safe for people with this condition.
For: Systemic SclerosisUnited States · Belgium · Canada - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open-label trial of the long-term safety and tolerability of nintedanib per os, on top of standard of care, over at least 3 years, in children and adolescents with clinically significant fibrosing Interstitial Lung Disease (InPedILD®-ON)
This study looks at a medicine called nintedanib for children and young people with a serious lung condition called Interstitial Lung Disease (ILD). It aims to check its long-term safety over at least three years, alongside their usual care, to see how well it's tolerated.
For: Childhood Interstitial Lung DiseaseBelgium · Portugal · Italy